Bial R&D Investments, S.A. — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications2liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BIA 28-6156This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.	Parkinson	À vérifier	À vérifier	United States, Italy, Portugal, Spain, United Kingdom	À vérifier
BIA 28-6156 10 mgThe purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).	Parkinson	Phase 2	Ralentissement de la progression	United States, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, …	À vérifier
BIA 28-6156 60 mgThe purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).	Parkinson	Phase 2	Ralentissement de la progression	United States, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, …	À vérifier
BIA 28-6156This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.	Parkinson	À vérifier	À vérifier	United States, Italy, Portugal, Spain, United Kingdom	À vérifier
BIA 28-6156 10 mgThe purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).	Parkinson	Phase 2	Ralentissement de la progression	United States, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
BIA 28-6156 10 mg	Parkinson	Phase 2	NCT05819359	ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	COMPLETED
BIA 28-6156	Parkinson	À vérifier	NCT07522606	Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study	NO_LONGER_AVAILABLE

Publications

2

Molécule	Indication / population	Titre	Journal	Date
BIA 28-6156		A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.	Movement disorders : official journal of the Movement Disorder Society
BIA 28-6156		A Randomized, Double-Blinded, Placebo-Controlled QTc Study to Evaluate BIA 28-6156 Effect on Cardiac Repolarization in Healthy Volunteers.	Clinical pharmacology in drug development